RxDoctor Payments Data

Edwin McLaughlin, DPM

Podiatrist · Attleboro, MANPI 1790705457

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,758 of the $2,275 with a category attached, or 77.3%. 18 manufacturers reported payments, led by Zimmer Biomet at 49.0% of the total. Reporting peaked in 2022 at $708 and has fallen 80.7% since, to $136 in 2025.

$2,275in general payments, 2019–2025

Across 59 payments — averaging $38.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$1K
  • Medtronic$210
  • International Life Sciences$145
  • Pfizer$125
  • Osiris Therapeutics Inc.$118
  • Kerecis Limited$110
  • plus $453 from 12 others

What the payments were for

  • Travel & lodging$51723%
  • Food & beverage$1,75877%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,275 in reported general payments places this provider in the 75th percentile of 179 podiatrist providers in Massachusetts.

See all podiatrist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$238,332
Medicare patients
626
Services billed
2,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pregabalin24$807
Gabapentin74$520
Clotrimazole17$482
Terbinafine Hcl45$353
Cephalexin18$283
Amitriptyline Hcl24$221
Ammonium Lactate14$152
Meloxicam23$26

Paid to pharmacies, not to this prescriber.

Other podiatrist in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →